Cargando…

Plasma Metabolite Signature Classifies Male LRRK2 Parkinson’s Disease Patients

Parkinson’s disease (PD) is a progressive neurodegenerative disease, causing loss of motor and nonmotor function. Diagnosis is based on clinical symptoms that do not develop until late in the disease progression, at which point the majority of the patients’ dopaminergic neurons are already destroyed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dong, Chen, Honrao, Chandrashekhar, Rodrigues, Leonardo O., Wolf, Josephine, Sheehan, Keri B., Surface, Matthew, Alcalay, Roy N., O’Day, Elizabeth M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8876175/ https://www.ncbi.nlm.nih.gov/pubmed/35208223 http://dx.doi.org/10.3390/metabo12020149

Ejemplares similares

Gadolinium-Based Paramagnetic Relaxation Enhancement Agent Enhances Sensitivity for NUS Multidimensional NMR-Based Metabolomics
por: Honrao, Chandrashekhar, et al.
Publicado: (2021)

LRRK2 kinase activity regulates GCase level and enzymatic activity differently depending on cell type in Parkinson’s disease
por: Kedariti, Maria, et al.
Publicado: (2022)

Subnormal GM1 in PBMCs: Promise for Early Diagnosis of Parkinson’s Disease?
por: Alselehdar, Samar K., et al.
Publicado: (2021)

Urinary proteome profiling for stratifying patients with familial Parkinson’s disease
por: Virreira Winter, Sebastian, et al.
Publicado: (2021)

An Assessment of LRRK2 Serine 935 Phosphorylation in Human Peripheral Blood Mononuclear Cells in Idiopathic Parkinson’s Disease and G2019S LRRK2 Cohorts
por: Padmanabhan, Shalini, et al.
Publicado: (2020)

Attitudes Toward Telehealth Services Among People Living With Parkinson's Disease: A Survey Study
por: Xu, Yaqian, et al.
Publicado: (2022)

Changes to Intermediary Metabolites in Sporadic and LRRK2 Parkinson's Disease Demonstrated by Proton Magnetic Resonance Spectroscopy
por: Aasly, Jan O., et al.
Publicado: (2015)

Association of Dual LRRK2 G2019S and GBA Variations With Parkinson Disease Progression
por: Ortega, Roberto A., et al.
Publicado: (2021)

Models for LRRK2-Linked Parkinsonism
por: Li, Tianxia, et al.
Publicado: (2011)

The role of the LRRK2 gene in Parkinsonism
por: Li, Jie-Qiong, et al.
Publicado: (2014)

LRRK2 and Proteostasis in Parkinson’s Disease
por: Pérez-Carrión, María Dolores, et al.
Publicado: (2022)

Targeting LRRK2 in Parkinson’s disease
por: Xiao, Bin, et al.
Publicado: (2022)

Metabolomic Profiling in LRRK2-Related Parkinson's Disease
por: Johansen, Krisztina K., et al.
Publicado: (2009)

Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease
por: Lai, Dongbing, et al.
Publicado: (2021)

Exploring cancer in LRRK2 mutation carriers and idiopathic Parkinson's disease
por: Warø, Bjørg Johanne, et al.
Publicado: (2017)

Rare variants in LRRK1 and Parkinson's disease
por: Schulte, Eva C., et al.
Publicado: (2013)

The Role of LRRK2 in Neurodegeneration of Parkinson Disease
por: Rui, Qin, et al.
Publicado: (2018)

LRRK2 and the Endolysosomal System in Parkinson’s Disease
por: Erb, Madalynn L., et al.
Publicado: (2020)

LRRK2 at the Crossroad of Aging and Parkinson’s Disease
por: Hur, Eun-Mi, et al.
Publicado: (2021)

Pathological Functions of LRRK2 in Parkinson’s Disease
por: Jeong, Ga Ram, et al.
Publicado: (2020)

Modeling Parkinson’s disease in LRRK2 rodents
por: Domenicale, Chiara, et al.
Publicado: (2023)

Structure of LRRK2 in Parkinson’s disease and model for microtubule interaction
por: Deniston, CK, et al.
Publicado: (2020)

Plasma Glucosylsphingosine in GBA1 Mutation Carriers with and without Parkinson's Disease
por: Surface, Matthew, et al.
Publicado: (2021)

LRRK2 and α-Synuclein: Distinct or Synergistic Players in Parkinson’s Disease?
por: O’Hara, Darren M., et al.
Publicado: (2020)

Differential Phospho‐Signatures in Blood Cells Identify LRRK2 G2019S Carriers in Parkinson's Disease
por: Garrido, Alicia, et al.
Publicado: (2022)

Brainstem neuromelanin and iron MRI reveals a precise signature for idiopathic and LRRK2 Parkinson’s disease
por: Martínez, Martín, et al.
Publicado: (2023)

Analysis of DNM3 and VAMP4 as genetic modifiers of LRRK2 Parkinson’s disease
por: Brown, Emmeline E., et al.
Publicado: (2021)

The impact of COVID-19 and social distancing on people with Parkinson’s disease: a survey study
por: Feeney, Megan P., et al.
Publicado: (2021)

Fibroblast Biomarkers of Sporadic Parkinson’s Disease and LRRK2 Kinase Inhibition
por: Smith, G. A., et al.
Publicado: (2015)

What Have We Learned from Cerebrospinal Fluid Studies about Biomarkers for Detecting LRRK2 Parkinson’s Disease Patients and Healthy Subjects with Parkinson’s-Associated LRRK2 Mutations?
por: Loeffler, David A., et al.
Publicado: (2019)

LRRK2 in Parkinson's disease and dementia with Lewy bodies
por: Zhu, Xiongwei, et al.
Publicado: (2006)

Genetic Variants of LRRK2 in Taiwanese Parkinson’s Disease
por: Wu, Yih-Ru, et al.
Publicado: (2013)

LRRK2 and neuroinflammation: partners in crime in Parkinson’s disease?
por: Russo, Isabella, et al.
Publicado: (2014)

LRRK2 contributes to monocyte dysregulation in Parkinson’s disease
por: Bliederhaeuser, Corinna, et al.
Publicado: (2016)

Roco Proteins and the Parkinson’s Disease-Associated LRRK2
por: Liao, Jingling, et al.
Publicado: (2018)

LRRK2 and membrane trafficking: nexus of Parkinson’s disease
por: Hur, Eun-Mi, et al.
Publicado: (2019)

Parkinson's disease and mitophagy: an emerging role for LRRK2
por: Singh, Francois, et al.
Publicado: (2021)

Generalized dystonia without Parkinsonism in an LRRK2 carrier
por: Díaz-Feliz, Lola, et al.
Publicado: (2022)

LRRK2 and Lipid Pathways: Implications for Parkinson’s Disease
por: Galper, Jasmin, et al.
Publicado: (2022)

Mitochondrial DNA damage as a potential biomarker of LRRK2 kinase activity in LRRK2 Parkinson’s disease
por: Gonzalez-Hunt, C. P., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1jc82ilfdhs17oc3o929l6j8rv